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Abstract: Antiretroviral drugs have saved and extended the lives of millions of individuals 
infected with HIV . The major classes of anti-HIV drugs include reverse transcriptase inhibitors, 
protease inhibitors, integrase inhibitors, and entry/fusion inhibitors. While antiretroviral drug 
regimens are not commonly used to treat other types of retroviral infections, there are instances 
where there is a perceived need for re-evaluation of the benefits of antiretroviral therapy. One 
case in point is that of feline leukemia virus (FeLV), an infection of companion felines. While 
vaccines exist to prevent FeLV infection and spread, they have not eliminated FeLV infection. 
For FeLV-infected felines and their human companions, antiretroviral therapy would be desirable 
and of practical importance if good options were available. Here, we discuss FeLV biology and 
current treatment options, and propose that there is a need for antiretroviral treatment options 
for FeLV infection. The comparative use and analysis of antiretroviral therapy can provide new 
insights into the mechanism of antiretroviral drug action.
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Introduction
Retroviruses are a large group of RNA viruses that are found in all vertebrates. They 
share many common features, such as similarities in genetic organization and mecha-
nism of replication, and in particular for their encoding for a reverse transcriptase. 
These viruses are a significant source of morbidity and mortality in both humans and 
animals. In humans, HIV is responsible for a world-wide pandemic that continues 
to be a significant cause of morbidity and mortality worldwide. In animals, feline 
leukemia virus (FeLV) represents a significant source of mortality and is the lead-
ing cause of infectious deaths in cats. Besides its role in feline mortality, FeLV has 
played an important role in advancing the understanding of retroviruses in general. In 
fact, the characterization of FeLV as well as other animal retroviruses such as bovine 
leukemia virus and Rous sarcoma virus, led to the concepts and techniques that later 
enabled the discovery and characterization of human retroviruses including HIV .1 
Additionally, FeLV was 1) the first retrovirus in which a vaccine was developed, 
2) the first retrovirus for which a practical diagnostic test was developed, and 3) the 
first retrovirus that elicited the development of a program whose goal was to control 
its spread.1 Despite the significant achievements and understanding of FeLV biol-
ogy, FeLV is still a significant source of morbidity and mortality in felines and the 
treatment options for infected cats are ineffective, toxic, or cost-prohibited. Here, we 
discuss FeLV epidemiology, pathogenicity, and current treatments as well as future 
drug targets that may advance the field of FeLV treatment.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Epidemiology
FeLV is highly transmissible through saliva and nasal secre-
tions as well as through coitus and vertical transmission from 
queen to kitten. Because the primary mode of transmission 
is through the oronasal route, its prevalence is often dictated 
by the extent of animal-to-animal contact. For example, the 
high prevalence of FeLV in the stray cat population (40%) 
increases the risk of infection for indoor–outdoor cats 
compared to indoor-only cats. Similarly, animal-to-animal 
contact contributes to the different rates of FeLV infection 
in single cat households (4%–11%) compared to multicat 
households whose prevalence has been reported to be as 
high as 70%.2,4,5
Containment of FeLV is difficult due to transmission 
routes, the time between infection and the onset of symp-
toms, and the ability of latently infected cats to become 
viremic. In fact, exposure of cats to FeLV usually leads to 
one of three outcomes, two of which can contribute to the 
spread of disease.2–8 The first outcome is accounted for by 
the 10% of exposed cats that become latently infected with-
out a detectable viremia. While these cats would not seem 
to be a source of infection, they can become viremic, and 
subsequently shed virus into the environment. The second 
outcome is represented by 40% of cats exposed to FeLV, 
and is characterized by persistent viremia and antigenemia. 
These cats are chronically infected, and therefore represent 
a significant source of viral shedding in the environment. 
The third outcome includes cats that become infected with 
FeLV , but are then able to clear the virus to the point where it 
is undetectable by standard testing methods. Approximately 
50% of cats exposed to FeLV fall into this last group and these 
cats are not considered to be a reservoir for viral spread.2,4
FeLV replication
FeLV was first described by Jarrett et al in 1964 who isolated 
viral particles from lymphomas obtained from infected 
cats.9 Using electron microscopy, Jarrett et al described the 
infectious agent as being similar in appearance to murine 
leukemia virus (MuLV). Later studies confirmed FeLV to be 
a retrovirus. FeLV is a “simple” retrovirus, in that it encodes 
for 3 genes common to all retroviruses (gag, pol, and env), 
but lacks many of the additional genes found in complex 
retroviruses such as HIV .6,7,10 As with other retroviruses, the 
gag gene encodes for structural proteins while the pol gene 
encodes for the enzymatic proteins necessary for reverse 
transcription of the FeLV genome, integration of its DNA 
into the host genome, and processing of viral proteins. 
Finally, env encodes for 2 envelope proteins that determine 
cellular tropism, including p15E, a transmembrane protein, 
and the associated external envelope protein, gp70.1 Amino 
acid variation in the virus envelope protein has led to the 
division of FeLV into 4 different subtypes that defines their 
cell tropism: A, B, C, and T (see Table 1).11–13 Subtype A is 
considered to be the founder, transmitted form of FeLV , with 
all other subtypes arising through mutations in FeLV-A Env or 
by recombination events with one of the endogenous FeLVs 
(enFeLV) contained within the cat genome.1,14 The enFeLV 
has an incomplete genome, is not replication competent, 
and is theorized to have originated hundreds of thousands 
of years ago when a cat ate a mouse that was viremic with 
murine leukemia virus (MuLV). Such an event enabled the 
incorporation of the MuLV genome into the genome of the 
cat’s germ line cells.15,16
Cell-free FeLV gains entry into target cells when the 
envelope protein binds to the appropriate host receptor that is 
dependent on the FeLV subtype (Table 1). Once inside of the 
target cell, the RNA genome is reverse transcribed into viral 
DNA by the viral protein reverse transcriptase.17–20 The viral 
DNA is then transported into the nucleus where it integrates 
into the host genome through the enzymatic action of viral 
integrase. The integrated viral DNA is then transcribed to pro-
duce RNA that serves as both viral progeny as well as mRNA 
for the translation of viral proteins. Translated Gag and Pol 
proteins are then trafficked to the cell membrane where 
the new virions bud from the cell membrane. As the virion 
buds, proteolytic cleavage of viral proteins causes structural 
changes in the virion that are necessary for viral maturation 
and the formation of infectious virus particles.17–20
Pathobiology
FeLV usually enters the feline host through the oronasal 
route either through mutual grooming, biting, or a shared 
food source.21–23 In the pharynx, FeLV infects the tonsillary 
B-lymphocytes and monocytes which can enter the draining 
lymph nodes.24 The draining lymph nodes serve as a site of 
replication and as an entry point for the virus to enter the 
bloodstream. Once in the bloodstream, the virus can gain 
access to and infect cells in the bone marrow.1 This represents 
a critical point in the infection process as it is thought that 
a persistent infection can be avoided if the immune system 
can mount an appropriate response before cells in the bone 
marrow are infected.25 Once the virus becomes systemic, it 
infects epithelial cells in the intestines, stomach, trachea, and 
salivary glands and is shed into the   environment.   Persistently Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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infected cats can demonstrate symptoms of disease any-
where from weeks to years after infection. FeLV-mediated 
disease   typically falls into one of two major categories – 
  cytoproliferative or immunosuppressive.1
Cytoproliferative diseases associated with FeLV include 
leukemias, lymphomas, fibrosarcoma, and associated myelo-
proliferative disorders.4,26 Most cytoproliferative diseases are 
attributed to insertional mutagenesis, a process by which 
FeLV DNA integrates at a site in the cat’s genome that dis-
rupts or deregulates expression of proteins involved in the 
regulation of cell cycle, cell survival, or apoptosis.27–32 In 
contrast, FeLV plays an indirect role in the formation of feline 
fibrosarcoma. Specifically, fibrosarcoma is caused by dual 
infection by both FeLV and feline sarcoma virus (FSV). FSV 
is a replication-defective virus that encodes an oncogene that 
drives cellular transformation.33–36 Therefore, FeLV serves as 
a helper virus, providing FSV with the proteins necessary 
for its replication, thereby allowing for expression of the 
FSV oncogene.33–36
Besides having cytoproliferative effects, FeLV also 
mediates a significant loss of immune function. This 
immune suppression is due to a progressive loss of T and 
B lymphocytes as well as neutrophils. Immune suppres-
sion leads to secondary infections such as bacterial or 
fungal infections that would not be a significant source of 
morbidity in an otherwise healthy cat.37–40 Although the 
exact mechanism of FeLV-mediated immunosuppression 
is not clear, evidence supports 3 distinct mechanisms of 
action. First, immune suppression may be a result of FeLV-
mediated myeloproliferative disorder.2,14 This disorder leads 
to an over-proliferation of incompetent mature or immature 
white blood cells within the bone marrow that eventually 
overcrowd hematopoietic cells, thereby decreasing red 
blood cell production and leading to a hindrance of the 
immune system. Second, the virus may be cytopathic or 
induce cellular apoptosis, although most   evidence indicates 
that this may be specific for FeLV subtype T. Third, it has 
been suggested that the transmembrane envelope protein, 
p15E, may have immunosuppressive properties.41–44 For 
example, p15E has been reported to inhibit production 
of mitogenic lymphokines in T cells and has been shown 
to inhibit lymphocyte function without affecting receptor 
function.42,43 Additionally, while p15E is not known to be 
cytotoxic, lymphocyte populations that are exposed to FeLV 
decline in size.41–44 FeLV-mediated immunosuppression 
allows for secondary infections such bacterial, parasitic, 
and other viral infections. One example includes the blood 
borne parasitic infection, hemobartonellosis, which is seen 
with the subgroup C infections and results in anemia with 
a hemolytic aspect.1
Other diseases are associated with FeLV in which the 
mechanisms remain unclear. For example, neurological dis-
eases and infertility are seen in FeLV-infected cats, though 
it is not clear how FeLV replication causes these disorders. 
Also, FeLV-C is known to cause a nonregenerative aplas-
tic anemia. While the mechanism is not clear, it has been 
suggested that the anemia may be due to FeLV’s use of the 
heme export receptor, FLVCR1, leading to a toxic accumu-
lation of heme in erythroid progenitor cells and decreasing 
their numbers.45,46 Figure 1 provides a summary of FeLV 
pathogenesis.
Therapeutics: vaccines  
and limitations
Besides containment of infected cats, commercially 
available vaccines for FeLV such as Pfizer’s Leukocell® 
or Merial’s Purevax® are marketed and may significantly 
reduce FeLV spread and viral reservoir development. These 
Table 1 Description of feline leukemia virus (FeLV) subtypes, their tropism, and prevalence in infected cats
FeLV subtypea Tropism Receptor used 
for entry
Prevalence in 
infected cats
Other
A Kidney, liver, T-cells,  
small intestines
THTR1 (thiamine  
transport protein)
100% Considered original transmitted FeLV
B Wide range of tissues Pit1 and Pit2 Occurs with FeLV A  
in 49% of infected cats
Arose through recombination  
of FeLV A and endogenous sequences
C Erythroid progenitor cells FLVCR1 (heme 
exporting protein)
1% Arose through mutations in FeLV A env
T T cells Pit1 in combination 
with co-receptor, 
FeLix
Unknown Arose from evolution of FeLV A 
(mutation and recombination)
Notes: aThe four subtypes of FeLV arose through mutation and recombination. Each subtype uses different host receptors for cell entry, resulting in different tissue tropism. 
For more information on FeLV subtypes, see text and references therein.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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particular vaccines are derived from chemically inactivated 
antigens or are of recombinant viral origin, respectively, 
and do not offer sterilizing immunity (ie, these vaccines 
essentially prime the cat’s immune system enabling it 
to clear the virus upon exposure).8,47,48 The American 
  Association of Feline Practitioners reserves the vaccination 
regimen for high-risk populations such as indoor–outdoor 
cats and catteries rather than including it as part of the 
core vaccines.
There are several reasons why these FeLV vaccines are 
likely reserved strictly for the high-risk populations. The 
link between FeLV vaccine and feline sarcoma is likely to 
play an important role in why these vaccines are not part 
of the core vaccines. Vaccine-associated sarcoma (VAS) is 
an aggressive malignant tumor which requires aggressive 
surgery and often chemotherapy to treat.2,14,49 The associa-
tion of VAS is a significant reason why many owners and 
breeders choose not to vaccinate their cats against FeLV. 
A second reason why the FeLV vaccine is not part of the 
core vaccines is that a closed population of indoor-only cats 
is not susceptible to FeLV , making the risk of VAS greater 
than the risk of infection. A third factor that might limit the 
use of the FeLV vaccine is that its efficacy is still not known 
and is difficult to determine. Further complicating the issue 
is that the biological response to FeLV exposure differs sig-
nificantly among cats. For example, 50% of cats clear the 
virus, 40% become persistently infected, and another 10% 
become latently infected. Finally, efficacy may need to be 
determined by using age-matched groups, given that younger 
cats are more susceptible to a pathogenic infection than older 
individuals.2,14,50 Analyzing the result from studies that have 
examined efficacy is difficult because of the differences in 
the study design, viral strain used, and age at which cats were 
challenged with virus.
Many owners choose not to vaccinate their cats for 
fear of VAS and because the efficacy of the vaccine is not 
clear. The unvaccinated cat population as well as the stray 
cat population remains at risk for FeLV and is a significant 
source for FeLV transmission. The prevalence of FeLV in 
the cat population is evident in veterinary care where there 
is a significant demand for the treatment of FeLV .
Therapeutics: antiviral drug targets 
and opportunities
The lack of effective treatment options leads most owners 
to choose palliative care for FeLV-infected cats. Pallia-
tive care may include medications to treat infections, pain 
management, nutritional support, or any other care with the 
goal of keeping the cats comfortable and improving their 
quality of life.
Although some antivirals and immune modulators 
have been reported to improve the quality or quantity of 
life for FeLV infected cats, no studies have convincingly 
shown that any antivirals or immune modulators actually 
improve the quality or quantity of life for FeLV-infected 
felines in a clinically useful form. Among antivirals used 
to treat FeLV , azidothymidine (AZT) was the first antiret-
roviral used to treat HIV. AZT is a nucleoside analog that 
becomes incorporated into the viral DNA during reverse 
transcription of the RNA genome to double-stranded 
DNA. AZT lacks the 3′ hydroxyl group necessary for 
DNA polymerization, which results in termination of viral 
DNA synthesis. Although AZT is the primary antiviral 
used clinically to treat FeLV, there is little, if any, literature 
to support its ability to improve the course of the disease 
once infection is established. Some studies have sug-
gested that treatment of cats 24 hours prior to infection 
up until 24 hours after infection might delay or minimize 
infection,51,52 but there have been no well-designed studies 
to address the efficacy of AZT to prolong the lives of cats 
with established infection. The studies that indicate that 
AZT might be efficacious demonstrated that even minor 
improvements in disease indicators were associated with 
drug-related toxicities. For example, animals treated with 
daily doses of 30 and 60 mg/kg had elevated antibody titers, 
suggesting that their immune system was better able to 
respond to infection, although all animals receiving these 
doses demonstrated drug-related toxicities.53 Thus, the 
main limitation for the use of AZT is its lack of apparent 
efficacy at tolerable doses.
Similar to antivirals, studies reporting the efficacy 
of immune modulators, lack appropriate controls and/or 
have not been independently verified. One of the immune 
modulators with little to no support for efficacy is lym-
phocyte T-cell immune modulator (LTCI). LTCI is a 
protein produced by a thymic stromal epithelial cell line 
whose manufacturers claim induces cytokines that activate 
CD8 cytotoxic T cells to attack virally infected cells. It is 
also claimed that LTCI leads to clinical improvement in 
FeLV-infected cats. These claims are not documented in 
the peer-reviewed literature, and the data supplied by the 
manufacturers do not argue strongly for improvements that 
would translate into an improvement in the quality of life 
or length of life for FeLV-infected animals.54
Another immune modulator, inactivated parapox ovis 
virus, strain D1701 (Baypamun®, Bayer, Leverkusen, Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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FeLV exposure through oral/nasal route
FeLV infects and replicates in tonsillary and pharyngeal lymphoid tissue
Infected cells filter into lymph nodes where virus replicates and enters bloodstream
Viremia
Other
Immunosuppressive effects Cytoproliferative effects
Lymphoma
Leukemia
Insertional
mutagenesis
FeLV facilitates
expression of
FSV oncogene
Myeloproliferative
disorders
Feline sarcoma
– thymic
– multicentric
Anemia
– nonregenerative
– (hemolysis from
  subtype C)
– regenerative
– chronic inflammation
– myelodestruction
– myelosuppression
– alimentary
– Neurological
– Infertility
– Enteropathy
– anodal
Virus enters bone marrow
and infects progenitor cells
Virus infects epithelial cells in tissues
(salivary glands, stomach, esophagus, intestines)
Secondary infections
– Mycoplasma haemofelis
– Chronic bacterial infections
– Calicivirus
– Feline infectious peritonitis
– Dermatophytosis
– Toxoplasma gondii
Figure 1 Pathogenesis of feline leukemia virus (FeLV) showing common entry route of virus, sites of viral replication, and pathological consequences of infection.
  Germany), is reported to nonspecifically activate the immune 
system and improve or cure FeLV-infected cats. Baypamun 
is reported to increase neutrophil counts and increase the 
production of interferon, interleukins, and tumor necrosis 
factor. While initial reports by Hörber and Mayr and   Hörber 
et al reported that Baypamun cured 80% to 100% of FeLV-
infected cats,55,56 numerous independent studies have failed 
to find a difference in clinical response between cats treated 
with Baypamun and those treated with placebo.57
Staphylococcus protein A (SPA) is perhaps the only 
immune modulator with evidence to support its ability to 
improve FeLV-infected cats. SPA is a bacterial polypeptide 
purified from the cell walls of Staphylococcus aureus Cowan 
I. Although its mechanism of action is not clear, it has been 
shown to bind preferentially to IgG in the form of an immune 
complex rather than its monomeric form. It has been specu-
lated that SPA may bind to IgG that is bound to a “blocking 
factor” associated with antigen–antibody   complexes and that 
this blocking factor may facilitate tumor or virus escape from 
immunological control. Therefore, SPA removes antigen–
antibody-blocking factor complexes, allowing the immune 
system to react to viral invasion. Others have suggested that Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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SPA may stimulate the immune system by inducing antibody 
synthesis, expression of interferon, and by potentiating the 
natural killer activity of lymphocytes. Although some stud-
ies have shown that SPA can improve the life expectancy 
of FeLV-infected cats, the treatment regimens described 
in these studies are too cost-prohibitive and demanding to 
be clinically useful.58 For example, the treatment regimens 
required whole-body irradiation followed by treatments 
given twice weekly. Additionally, it took 14 to 45 treatments 
to clear the virus and even this many treatments did not 
elicit a response from all of the cats.59 Given the conflict-
ing results on treatment efficacy in addition to the cost and 
time associated with the treatments, SPA is not a clinically 
feasible treatment option.
Treatment options, drug targets, 
and the need for FeLV-based 
antiretrovirals
The significant morbidity and mortality associated with 
FeLV combined with the significant knowledge of FeLV 
biology and availability of antiretrovirals developed for 
HIV should facilitate the identification and development 
of new treatment options for FeLV. Perhaps one of the 
main problems with treating FeLV is that early treatment 
is almost a prerequisite for success. Since insertional 
mutagenesis is responsible for FeLV-mediated lympho-
mas and leukemias, a quick decrease in viral loads would 
ensure fewer integration events, thereby decreasing the 
likelihood of oncogenesis. Given the success in anti-HIV 
drugs at quickly decreasing viral loads, it is reasonable to 
assume that some of these drugs could be repositioned for 
the treatment of FeLV. The most likely classes of anti-HIV 
drugs that could be repositioned include the nucleoside 
reverse transcriptase inhibitors (NRTIs). Many of the 
other classes of anti-HIV drugs are structure-based small-
molecule inhibitors and would therefore be unlikely to 
possess anti-FeLV activities. Although there are a number 
of NRTIs that could be repositioned to treat FeLV , in vitro 
and in vivo studies indicate that NRTIs may not be readily 
repositioned to treat FeLV infections. Biochemical studies 
have shown that reverse transcriptase from oncoretroviruses 
such as FeLV have a higher fidelity and a significantly 
lower susceptibility to certain nucleoside analogs compared 
with lentiviruses.58 The differences in   susceptibility to 
nucleoside analogs between lentiviral reverse transcriptases 
and oncoretroviral reverse transcriptases suggest that 
nucleoside analogs used to treat HIV will have different 
susceptibilities for FeLV .
Conclusion
In human medicine, improvement in treatment options 
is driven by the demand of those affected by the disease. 
A prominent example of this demand and supply is seen 
with conditions such as cancer and HIV, where the impact 
on society fueled the funding and motivation necessary to 
rapidly expand treatment options in a short time. Although 
diseases of companion animals do not have the same affect 
on society as those that affect humans, there is an increasing 
awareness of the benefits of companion animals in improving 
the health and well-being of humans and a trend for demand-
ing better treatment options at whatever cost. Antiretroviral 
drugs and molecular tools are readily available to determine 
if drugs used to treat HIV could be repositioned to treat 
FeLV. An important factor in assessing and instituting these 
  potential treatments is adequate funding of well-designed 
studies that have sufficient numbers and controls to clearly 
define the treatment’s efficacy and potential toxicity.
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